EnteroMedics (NASDAQ:RSLS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

According to Zacks, “ReShape Lifesciences Inc. is a developer of invasive medical devices to treat obesity and metabolic diseases. The company’s portfolio includes vBloc System(R), ReShape(R) and Gastric Vest System (TM). ReShape Lifesciences Inc., formerly known as EnteroMedics Inc., is based in CA, United States. “

Separately, ValuEngine upgraded EnteroMedics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

Shares of EnteroMedics (NASDAQ:RSLS) opened at $1.37 on Wednesday. EnteroMedics has a 52-week low of $1.23 and a 52-week high of $30.41.

EnteroMedics (NASDAQ:RSLS) last released its quarterly earnings results on Tuesday, November 14th. The medical device company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.77). EnteroMedics had a negative net margin of 4,509.61% and a negative return on equity of 104.23%. The company had revenue of $0.36 million during the quarter. research analysts expect that EnteroMedics will post -1.97 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/06/enteromedics-rsls-lowered-to-sell-at-zacks-investment-research.html.

About EnteroMedics

ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.

Get a free copy of the Zacks research report on EnteroMedics (RSLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.